In brief: Rockeby, C3, Heartware
Friday, 04 March, 2005
Rockeby Biomed Limited (ASX:RBY) is poised to launch its Candia5 candidiasis diagnostic in Europe, having received ISO certification and CE Mark approval for the product.
Clinical Cell Culture (C3, ASX:CCE) has notched up the first commercial sale of spray-on-skin technology, ReCell, to its Japanese distributor and the announced the first use of ReCell in Japan. C3 Chief Executive Officer Troels Jordansen said the company had invoiced over AUD$400,000 in the first quarter of the calendar year in Japan.
HeartWare (ASX:HTW) has appointed corporate lawyer David McIntyre as chief financial officer and company secretary.
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
